SARS-CoV-2 is the causal agent of COVID-19 disease . Currently, infection with SARS-CoV-2 has been the cause of death of over 2.5 million people globally, and there is still no effective curative treatment . Clinically, the severe symptoms caused by COVID-19, in addition to pneumonia, are associated with the development of hyperinflammatory syndrome and thrombosis . It is urgent to expand our understanding of the molecular mechanisms involved in the pathophysiology of COVID-19 . This article discusses the potential role that the chemokine CX3CL1 could have in the development of COVID-19-associated thrombosis . CX3CL1 is abundantly expressed by activated endothelium and is an important regulator of many aspects of endothelial function and dysfunction, including thrombosis . The generation of hypotheses about molecules that could be relevant in well-defined aspects of the pathophysiology of COVID-19 encourages the development of basic and clinical studies, that could help find effective and much needed treatments.